Tumor growth and metastasis

Platelets

Volumn , Issue , 2007, Pages 769-778

  Nierodzik, Mary Lynn ^a,b   Karpatkin, Simon ^b  

^a BELLEVUE HOSPITAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 75949129616     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369367-9/50804-1     Document Type: Chapter

References (101)

1. Gasic G., Gasic T., Stewart C. Antimetastatic effects associated with platelet reduction. Proc Nat Acad Sci USA 1968, 46-52.
2. Gasic G.J., Gasic T.B., Galanti N., et al. Platelettumor-cell interactions in mice: The role of platelets in the spread of malignant disease. Int J Cancer 1973, 11:704-718.
3. Hilgard P. The role of blood platelets in experimental metastases. Br J Cancer 1973, 28:429-435.
4. Pearlstein E., Salk P.L., Yogeeswaran G., et al. Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10 metastatic-variant derivatives of a rat renal sarcoma cell line. Proc Nat Acad Sci USA 1980, 77:4336-4339.
5. Camerer E., Qazi A., Duong D., et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004, 104:397-401.
6. Hilgard P., Gordon-Smith E. Microangiopathic haemolytic anemia and experimental tumor-cell emboli. Br J Haematol 1974, 26:651-659.
7. Jones J., Wallace A., Fraser E. Sequence of events in experimental and electron microscopic observations. J Nat Cancer Inst 1991, 46:493-504.
8. Sindelar W., Tralka T., Ketcham A. Electron microscope observations on formation of pulmonary metastases. J Surg Res 1975, 18:137-161.
9. Warren B., Vales O. The adhesion of thromboplastic tumor emboli to vessel walls. in vivo. Br J Haematol 1972, 53:301-313.
10. Fitzpatrick F.A., Stringfellow D.A. Prostaglandin D2 formation by malignant melanoma cells correlates inversely with cellular metastatic potential. Proc Nat Acad Sci USA 1979, 76:1765-1769.
11. Gasic G.J., Boettiger D., Catalfamo J.L., et al. Aggregation of platelets and cell membrane vesiculation by rat cells transformed in vitro by Rous sarcoma virus. Cancer Res 1978, 38:2950-2955.
12. Gasic G.J., Gasic T.B., Jimenez S.A. Effects of trypsin on the platelet-aggregating activity of mouse tumor cells. Thromb Res 1977, 10:33-45.
13. Gasic G.J., Gasic T.B., Jimenez S.A. Platelet aggregating material in mouse tumor cells: Removal and regeneration. Lab Invest 1977, 36:413-419.
14. Gasic G.J., Koch P.A., Hsu B., et al. Thrombogenic activity of mouse and human tumors: Effects on platelets, coagulation, and fibrinolysis, and possible signifi cance for metastases. Z Krebs forsch Klin Onkol Cancer Res Clin Oncol 1976, 86:263-277.
15. Hara Y., Steiner M., Baldini M. Platelets as a source of growth-promoting factor (s) for tumor cells. Cancer Res 1980, 40:1212-1216.
16. Karpatkin S., Smerling A., Pearlstein E. Plasma requirement for the aggregation of rabbit platelets by an aggregating material derived from SV40-transformed 3T3 fibroblasts. J Lab Clin Med 1980, 96:994-1001.
17. Marcum J.M., McGill M., Bastida E., et al. The interaction of platelets, tumor cells, and vascular subendothelium. J Lab Clin Med 1980, 96:1046-1053.
18. Pearlstein E., Cooper L.B., Karpatkin S. Extraction and characterization of a platelet-aggregating material from SV40-transformed mouse 3T3 fibroblasts. J Lab Clin Med 1979, 93:332-344.
19. Fidler I. Metastases: Quantitative analysis of distribution and fate of tumor emboli labeled with 125I-5-iodo-2.-deoxyuridine. J Nat Cancer Inst 1970, 45:773-782.
20. Warren B. The microinjury hypothesis and metastasis. Hemostatic mechanisms and metastasis 1984, 56. M. Nijhoff, Boston.
21. Nieswandt B., Hafner M., Echtenacher B., Mannel D. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999, 59:1295-1300.
22. Palumbo J.S., Talmage K.E., Massari J.V., et al. Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005, 105:178-185.
23. Cowan D., Graham J. Effect of platelet growth factor(s) on growth of human tumor colonies 1982, 249-268. R. Alan, Liss, New York.
24. Eastman B., Sirbasku D. Platelet derived growth factor (s) for a hormone responsive rat mammary tumor cell line. J Cell Physiol 1981, 97:17-28.
25. Kepner N., Lipton A. A mitogenic factor for transformed fibroblasts from human platelets. Cancer Res 1981, 41:430-432.
26. Mohle R., Green D., Moore M., et al. Constitutive production and thrombin-induced release of VEGF by human megakaryocytes and platelets. Proc Nat Acad Sci USA 1997, 94:663-668.
27. Li J.-J., Huang Y.-Q., Basch R., et al. Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost 1998, 85:204-206.
28. Maloney J., Sillimon C., Ambruso D., et al. In vitro release of VEGF during platelet aggregation. Am J Physicians 1998, 275:H1054.
29. Boucharaba A., Serre C.M., Gres S., et al. Plateletderived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004, 114:1714-1725.
30. Lerner W., Pearlstein E., Ambrogio C., et al. A new mechanism for tumor-induced platelet aggregation: Comparison with mechanism shared by other tumors with possible pharmacologic strategy toward prevention of metastases. Int J Cancer 1983, 31:463-469.
31. Gasic G., Gasic T. Removal of sialic acid from the cell coat in tumor cells and vascular endothelium, and its effects on metastasis. Proc Nat Acad Sci USA 1962, 48:1172-1177.
32. Miller O.V., Aiken J.W., Shebuski R.J., et al. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent. Prostaglandins 1980, 20:391-400.
33. Tamao Y., Hara H., Kikumoto R., et al. The effect of the synthetic thrombin inhibitor, no. 805, on an experimental DIC in rabbits. Thromb Haemos 1981, 46.
34. Karpatkin S., Ambrogio C., Pearlstein E. Lack of effect of in vivo prostacyclin on the development of pulmonary metastases in mice following intravenous injection of CT26 colon carcinoma, Lewis lung carcinoma, or B16 amelanotic melanoma cells. Cancer Res 1984, 44:3880-3883.
35. Karpatkin S., Pearlstein E., Ambrogio C., et al. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation. in vivo. J Clin Invest 1988, 81:1012-1019.
36. Pearlstein E., Ambrogio C., Karpatkin S. Effect of anti-platelet antibody on the development of pulmonary metastases following injection of CT26 colon adenocarcinoma, Lewis lung carcinoma and B16 amelanotic melanoma tumor cells in mice. Cancer Res 1984, 44:3884-3887.
37. Biggerstaff J., Seth N., Amirkhosravi A., et al. Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis. Clin Exp Metastasis 1999, 17:723-730.
38. McCarty O., Mousa S., Bray P., et al. Immobilized platelets support human colon carcinoma cell tethering, rolling, and fi rm adhesion under dynamic flow conditions 2000, 96.
39. Aigner S., Ramos C., Hafezi-Moghadam A., et al. CD24 mediates rolling of breast carcinoma cells on Pselectin. FASEB J 1998, 12:1241-1251.
40. Aigner S., Sthoeger M., Fogel M., et al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells 1997, 89:3385-3395.
41. Kim Y., Borsig L., Varki N., et al. P-selectin defi-ciency attenuates tumor growth and metastasis. Proc Nat Acad Sci USA 1998, 95:9325-9330.
42. Nierodzik M., Plotkin A., Kajumo F., et al. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis. in vivo. J Clin Invest 1991, 87:229-236.
43. Nierodzik M., Kajumo F., Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and metastasis. in vivo. Cancer Res 1992, 52:3267-3272.
44. Wojtukiewicz M., Tang D., Ben-Josef E., et al. Solid tumor cells express functional tethered ligand thrombin receptor. Cancer Res 1995, 55:698-700.
45. Wojtukiewicz M., Tang D., Ciarelli J., et al. Thrombin increases the metastatic potential of tumor cells. Int J Cancer 1993, 54:793-806.
46. Klepfish A., Greco M.A., Karpatkin S. Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix. Int J Cancer 1993, 53:978-982.
47. Dardik R., Savion N., Kaufmann Y., et al. Thrombin promotes platelet-mediated melanoma cell adhesion to endothelial cells under flow conditions: Role of platelet glycoproteins P-selectin and GPIIb-IIIa. Br J Cancer 1998, 77:2069-2075.
48. Helland I., Klemensten B., Jorgensen L. Addition of both platelets and thrombin in combination accelerates tumor cells to adhere to endothelial cells in vitro. In Vitro Cell Dev Biol Anim 1997, 33:182-186.
49. Boukerche H., Berthier-Vergnes O., Tabone E., et al. Platelet-melanoma cell interaction is mediated by the glycoprotein IIb-IIIa complex. Blood 1989, 74:658-663.
50. Cheresh D., Spiro R. Biosynthetic and functional properties of an arg-gly-asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen and von Willebrand factor. J Biol Chem 1989, 262:17703-17711.
51. Grossi I., Hatfield J., FitzGerald L., et al. Presence of cytoadhesions (IIb-IIIa-like glycoproteins) on human metastatic melanomas but not on benign melanocytes. Am J Clin Pathol 1989, 92:495-499.
52. McGregor B.C., McGregor J.L., Weiss L.M., et al. Presence of cytoadhesins (IIb-IIIa-like glycoproteins) on human metastatic melanomas but not on benign melanocytes. Am J Clin Pathol 1989, 92:495-499.
53. Chen Y., Trikha M., Gao X., et al. Ectopic expression of platelet integrin alphaIIb beta3 in tumor cells from various species and histological origin. Int J Cancer 1997, 72:642-648.
54. Trikha M., Timar J., Lundy S., et al. The high affinity alphaIIb beta3 integrin is involved in invasion of human melanoma cells. Cancer Res 1997, 57:2522-2528.
55. Huang Y.Q., Li J.J., Hu L., et al. Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. Thromb Haemost 2001, 86:1094-1098.
56. Huang Y.Q., Li J.J., Hu L., et al. Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells. Blood 2002, 99:1646-1650.
57. Nierodzik M.L., Bain R.M., Liu L.-X., et al. Presence of the seven transmembrane thrombin receptor on human tumour cells: Effect of activation on tumour adhesion to platelets and tumour tyrosine phosphorylation. Br J Haematol 1996, 92:452-457.
58. Nierodzik M., Chen K., Takeshita K., et al. Proteaseactivated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 1998, 92:3694-3700.
59. Shi X., Gangadharan B., Brass L.F., et al. Proteaseactivated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Molecules Cancer Res 2004, 2:395-402.
60. Yoshida E., Verrusio E.N., Mihara H., et al. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. Cancer Res 1994, 54:3300-3304.
61. Shankar R., de la Motte C.A., Poptic E.J., et al. Thrombin receptor-activating peptides differentially stimulate platelet-derived growth factor production, monocytic cell adhesion, and E-selectin expression in human umbilical vein endothelial cells. J Biol Chem 1994, 269:13936-13941.
62. Colotta F., Sciacca F.L., Sironi M., et al. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol 1994, 144:975-985.
63. Grandaliano G., Valente A.J., Abboud H.E. A novel biologic activity of thrombin: Stimulation of monocyte chemotactic protein production. J Exp Med 1994, 179:1737-1741.
64. Glembotski C.C., Irons C.E., Krown K.A., et al. Myocardial alpha-thrombin receptor activation induces hypertrophy and increases atrial natriuretic factor gene expression. J Biol Chem 1993, 268:20646-20652.
65. Bartha K., Brisson C., Archipoff G., et al. Thrombin regulates tissue factor and thrombomodulin mRNA levels and activities in human saphenous vein endothelial cells by distinct mechanisms. J Biol Chem 1993, 268:421-429.
66. Carney D., Glenn K., Cunningham D. Conditions which affect initiation of animal cell division by trypsin and thrombin. J Cell Physiol 1978, 95:13-22.
67. Carney D., Stiernberg J., Fenton J. Initiation of proliferative events by human α-thrombin requires both receptor binding and enzymatic activity. J Cell Biochem 1984, 26:181-195.
68. Chen L., Buchanan J. Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc Nat Acad Sci USA 1975, 72:131-135.
69. Glenn K., Carney D., Fenton J., et al. Thrombin active site regions required for fibroblast receptor binding and initiation of cell division. J Biol Chem 1980, 255:6609-6616.
70. Gospodarowicz D., Brown K., Birdwell C., et al. Control of proliferation of human vascular endothelial cells: Characterization of the response of human umbilical vein endothelial cells to fibroblast growth factor, epidermal growth factor, and thrombin. J Cell Biol 1978, 77:774-788.
71. Morris D., Ward J., Carney D. Thrombin promotes cell transformation in Balb 3T3/A 31-1-13 cells. Carcinogenesis 1992, 13:67-73.
72. Lampugnani M.G., Colotta F., Polentarutti N., et al. Thrombin induces c-fos expression in cultured human endothelial cells by a Ca2 (+) -dependent mechanism. Blood 1990, 76:1173-1180.
73. Dorn G.W., Davis M.G. Thrombin, but not thromboxane, stimulates megakaryocytic differentiation in human megakaryoblastic leukemia cells. J Pharmacol Exp Ther 1992, 262:1242-1247.
74. Kramer R., McDonald K., Crowley E., et al. Melanoma cell adhesion to basement membrane mediated by integrin-related complexes. Cancer Res 1989, 49:393-402.
75. Chan B., Matsuura N., Takada Y. In vitro and in vivo consequences of VLA-2 expression on rhabdomyosarcoma cells. Science 1991, 251:1600-1602.
76. Iwamoto Y., Robey F., Graf J. YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 1987, 238:1132-1134.
77. Kramer R., McDonald K., Vu M. Human melanoma cells express a novel integrin receptor for laminin. J Biol Chem 1989, 264:15642-15649.
78. Soszka T., Knudsen K., Beviglia L., et al. Inhibition of murine melanoma cell-matrix adhesion and experimental metastasis by albolabrin, an RGD-containing peptide isolated from the venom of Trimeresarus albolabris. Exp Cell Res 1991, 196:6-12.
79. Terranova V., Williams J., Liotta L. Modulation of metastatic activity of melanoma cells by laminin and fibronectin. Science 1984, 226:982-984.
80. Cheresh D., Smith W., Cooper H., et al. A novel vitronectin receptor integrin (avbx) is responsible for distinct adhesive properties of carcinoma cells. Cell 1989, 57:59-69.
81. Kramer R., Marks N. Identification of integrin collagen receptors on human melanoma cells. J Biol Chem 1989, 264:4684-4688.
82. Castler V., Varan J., Fligiel S. Anti-sense reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma. J Clin Invest 1991, 87:1883-1888.
83. Roberts D., Sherwood J., Ginsburg V. Platelet thrombospondin mediates attachment and spreading of human melanoma cells. J Cell Biol 1987, 104:131-139.
84. Kramer A., Keitel T., Winkler K., et al. Molecular basis for the binding promiscuity of an anti-p24 (HIV-1) monoclonal antibody. Cell 1997, 91:799-809.
85. Tuszynski G.P., Gasic T.B., Rothman V.L., et al. Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res 1987, 47:4130-4133.
86. Humphries M., Olden K., Yamada K. A synthetic peptide from fibronectin inhibits experimental metastases of murine melanoma cells. Science 1986, 467:467-470.
87. Humphries M., Yamada K., Olden K. Investigation of the biological effect of anti-cell adhesive synthetic peptides that inhibit experimental metastasis of B16F10 murine melanoma cells. J Clin Invest 1988, 81:782-790.
88. Bastida E., Ordinas A., Escolar G., et al. Tissue factor in microvesicles shed from U87 MG human glioblastoma cells induces coagulation, platelet aggregation and thrombogenesis. Blood 1984, 64:177-184.
89. Curatolo L., Colucci M., Cambini A., et al. Evidence that cells from experimental tumors can activate coagulation factor X. Br J Haematol 1979, 40:228-233.
90. Dvorak H., Van deWater L., Bitzer A., et al. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res 1983, 43:4334-4342.
91. Gordon S., Cross B. A factor X-activating cysteine protease from malignant tissue. J Clin Invest 1981, 67:1665-1671.
92. Honn K., Sloane B., Cavanaugh P. Role of the coagulation system in tumor-cell-induced platelet aggregation and metastasis. Haemostasis 1988, 18:37-46.
93. Kadish J., Wenc K., Dvorak H. Tissue factor activity of normal and neoplastic cells: Quantitation and species specificity. J Nat Cancer Inst 1983, 70:551-557.
94. Pearlstein E., Ambrogio C., Gasic G., et al. Inhibition of platelet aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor: Dansylarginine N- (3-ethyl-1,5-pentanediyl) amide. Cancer Res 1981, 41:4535-4539.
95. Yoda Y., Abe T. Fibrinopeptide A (FPA) level and fibrinogen kinetics in patients with malignant disease. Thromb Haemost 1981, 46:706-709.
96. Merskey C., Johnson A., Harris J., et al. Isolation of fibrinogen-fibrin related antigen from human plasma by immune-affinity chromatography: Its characterization in normal subjects and in defibrinating patients with abruptio placentae and disseminated cancer. Br J Haematol 1980, 44:655-670.
97. Peuscher F., Cleton F., Armstrong L., et al. Signifi-cance of plasma fibrinopeptide A (FPA) in patients with malignancy. J Lab Clin Med 1980, 96:5-14.
98. Rickles F., Edwards R., Barb C., et al. Abnormalities of blood coagulation in patients with cancer: Fibrinopeptide, a generation and tumor growth. Cancer 1983, 51:301-307.
99. Esumi N., Fan D., Fidler I. Inhibition of murine melanoma experimental metastasis by recombinantdesulfatohirudin, a highly specific thrombin inhibitor. Cancer Res 1981, 51:4549-4556.
100. Lee M., Campbell W., Huang Y.-Q., et al. Hirudin inhibits human tumor implantation and metastasis in nude mice. Blood 2000, 96:818A.
101. Karpatkin S. Hypercoagulability preceding cancer. Does hypercoagulability awaken dormant tumor cells in the host?. J Thromb Haemost 2005, 3:577-580.